Genetic approach for intracerebroventricular delivery

Proceedings of the National Academy of Sciences of the United States of America

Volumn 107, Issue 9, 2010, Pages 4424-4429

  Regev, Limor ^a   Ezrielev, Eli ^a   Gershon, Eran ^a   Gil, Shosh ^a   Chen, Alon ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

Blood brain barrier; Cerebrospinal fluid; Choroid plexus; Lentiviruses; Secreted peptides

Indexed keywords

CORTICOTROPIN RELEASING FACTOR; GENE PRODUCT; GONADORELIN; NEUROPEPTIDE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANXIETY; ARTICLE; CEREBROSPINAL FLUID; CHOROID PLEXUS; CLINICAL RESEARCH; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; EMBRYO; ESTRUS CYCLE; FEMALE; GENETICS; HUMAN; HUMAN CELL; LENTIVIRINAE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION;

ANIMALS; CELL LINE; GENETIC VECTORS; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; INJECTIONS, INTRAVENTRICULAR; LENTIVIRUS; MICE; PEPTIDES;

EID: 77749292139     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0907059107     Document Type: Article

References (53)

1. Saunders NR, Ek CJ, Habgood MD, Dziegielewska KM (2008) Barriers in the brain: A renaissance? Trends Neurosci 31:279-286.
2. PardridgeWM(2002) Drug and gene delivery to the brain: The vascular route. Neuron 36:555-558.
3. Pardridge WM (2007) Drug targeting to the brain. Pharm Res 24:1733-1744.
4. Johanson CE, Duncan JA, Stopa EG, Baird A (2005) Enhanced prospects for drug delivery and brain targeting by the choroid plexus-CSF route. Pharm Res 22: 1011-1037.
5. Emerich DF, Skinner SJ, Borlongan CV, Vasconcellos AV, Thanos CG (2005) The choroid plexus in the rise, fall and repair of the brain. Bioessays 27:262-274.
6. Brown PD, Davies SL, Speake T, Millar ID (2004) Molecular mechanisms of cerebrospinal fluid production. Neuroscience 129:957-970.
7. Chodobski A, Szmydynger-Chodobska J (2001) Choroid plexus: Target for polypeptides and site of their synthesis. Microsc Res Tech 52:65-82.
8. Gossen M, Bujard H (1992) Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc Natl Acad Sci USA 89:5547-5551.
9. Gossen M, et al. (1995) Transcriptional activation by tetracyclines in mammalian cells. Science 268:1766-1769.
10. Mansuy IM, Mayford M, Jacob B, Kandel ER, Bach ME (1998) Restricted and regulated overexpression reveals calcineurin as a key component in the transition from short-term to long-term memory. Cell 92:39-49.
11. Lovenberg TW, Chalmers DT, Liu C, De Souza EB (1995) CRF2 alpha and CRF2 beta receptor mRNAs are differentially distributed between the rat central nervous system and peripheral tissues. Endocrinology 136:4139-4142.
12. Chen A, et al. (2005) Mouse corticotropin-releasing factor receptor type 2alpha gene: Isolation, distribution, pharmacological characterization and regulation by stress and glucocorticoids. Mol Endocrinol 19:441-458.
13. Catalano RD, Kyriakou T, Chen J, Easton A, Hillhouse EW (2003) Regulation of corticotropin-releasing hormone type 2 receptors by multiple promoters and alternative splicing: Identification of multiple splice variants. Mol Endocrinol 17: 395-410.
14. Docherty K, Steiner DF (1982) Post-translational proteolysis in polypeptide hormone biosynthesis. Annu Rev Physiol 44:625-638.
15. Bittencourt JC, Sawchenko PE (2000) Do centrally administered neuropeptides access cognate receptors?: An analysis in the central corticotropin-releasing factor system. J Neurosci 20:1142-1156.
16. Vickery BH (1985) Comparisons of the potential utility of LHRH agonists and antagonists for fertility control. J Steroid Biochem 23 (5B):779-791.
17. Koch Y, et al. (1973) Production and characterization of an antiserum to synthetic gonadotropin-releasing hormone. Biochem Biophys Res Commun 55:616-622.
18. Costa RH, Lai E, Darnell JE, Jr. (1986) Transcriptional control of the mouse prealbumin (transthyretin) gene: both promoter sequences and a distinct enhancer are cell specific. Mol Cell Biol 6:4697-4708.
19. Pickering C, et al. (2008) The Adhesion GPCR GPR125 is specifically expressed in the choroid plexus and is upregulated following brain injury. BMC Neurosci 9:97-110.
20. Pardridge WM (2007) Blood-brain barrier genomics. Stroke 38 (2, Suppl):686-690.
21. Thouvenot E, et al. (2006) The proteomic analysis of mouse choroid plexus secretome reveals a high protein secretion capacity of choroidal epithelial cells. Proteomics 6: 5941-5952.
22. Enerson BE, Drewes LR (2006) The rat blood-brain barrier transcriptome. J Cereb Blood Flow Metab 26:959-973.
23. Naldini L, Blömer U, Gage FH, Trono D, Verma IM (1996) Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. Proc Natl Acad Sci USA 93:11382-11388.
24. Jakobsson J, Lundberg C (2006) Lentiviral vectors for use in the central nervous system. Mol Ther 13:484-493.
25. Naldini L, et al. (1996) In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 272:263-267.
26. Chauhan AN, Lewis PD (1979) A quantitative study of cell proliferation in ependyma and choroid plexus in the postnatal rat brain. Neuropathol Appl Neurobiol 5:303-309.
27. Pardridge WM (2007) shRNA and siRNA delivery to the brain. Adv Drug Deliv Rev 59: 141-152.
28. Spencer BJ, Verma IM (2007) Targeted delivery of proteins across the blood-brain-barrier. Proc Natl Acad Sci USA 104:7594-7599.
29. Seidah NG, Chrétien M (1999) Proprotein and prohormone convertases: A family of subtilases generating diverse bioactive polypeptides. Brain Res 848:45-62.
30. FugèreM, Day R (2005) Cutting back on pro-protein convertases: The latest approaches to pharmacological inhibition. Trends Pharmacol Sci 26:294-301.
31. Gee P, Rhodes CH, Fricker LD, Angeletti RH (1993) Expression of neuropeptide processing enzymes and neurosecretory proteins in ependyma and choroid plexus epithelium. Brain Res 617:238-248.
32. MacCumber MW, Snyder SH, Ross CA (1990) Carboxypeptidase E (enkephalin convertase): mRNA distribution in rat brain by in situ hybridization. J Neurosci 10: 2850-2860.
33. Schafer MK, Stoffers DA, Eipper BA, Watson SJ (1992) Expression of peptidylglycine alpha-amidating monooxygenase (EC 1.14.17.3) in the rat central nervous system. J Neurosci 12:222-234.
34. Schäfer MK, et al. (1993) Gene expression of prohormone and proprotein convertases in the rat CNS: a comparative in situ hybridization analysis. J Neurosci 13:1258-1279.
35. Hynes MA, Brooks PJ, Van Wyk JJ, Lund PK (1988) Insulin-like growth factor II messenger ribonucleic acids are synthesized in the choroid plexus of the rat brain. Mol Endocrinol 2:47-54.
36. Vale W, Spiess J, Rivier C, Rivier J (1981) Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin. Science 213:1394-1397.
37. Rivier C, Vale W (1983) Modulation of stress-induced ACTH release by corticotropin-releasing factor, catecholamines and vasopressin. Nature 305:325-327.
38. Sutton RE, Koob GF, Le Moal M, Rivier J, Vale WW (1982) Corticotropin releasing factor produces behavioural activation in rats. Nature 297:331-333.
39. Brown MR, et al. (1982) Corticotropin-releasing factor: Actions on the sympathetic nervous system and metabolism. Endocrinology 111:928-931.
40. Koob GF, Heinrichs SC (1999) A role for corticotropin releasing factor and urocortin in behavioral responses to stressors. Brain Res 848:141-152.
41. Holsboer F (1999) The rationale for corticotropin-releasing hormone receptor (CRH-R) antagonists to treat depression and anxiety. J Psychiatr Res 33:181-214.
42. Arborelius L, Owens MJ, Plotsky PM, Nemeroff CB (1999) The role of corticotropin-releasing factor in depression and anxiety disorders. J Endocrinol 160:1-12.
43. Holmes A, Heilig M, Rupniak NM, Steckler T, Griebel G (2003) Neuropeptide systems as novel therapeutic targets for depression and anxiety disorders. Trends Pharmacol Sci 24:580-588.
44. Bale TL (2005) Sensitivity to stress: dysregulation of CRF pathways and disease development. Horm Behav 48:1-10.
45. de Kloet ER, Joëls M, Holsboer F (2005) Stress and the brain: From adaptation to disease. Nat Rev Neurosci 6:463-475.
46. Davis M (1998) Are different parts of the extended amygdala involved in fear versus anxiety? Biol Psychiatry 44:1239-1247.
47. Griebel G, Perrault G, Sanger DJ (1998) Characterization of the behavioral profile of the non-peptide CRF receptor antagonist CP-154,526 in anxiety models in rodents. Comparison with diazepam and buspirone. Psychopharmacology (Berl) 138:55-66.
48. Amoss M, et al. (1971) Purification, amino acid composition and N-terminus of the hypothalamic luteinizing hormone releasing factor (LRF) of ovine origin. Biochem Biophys Res Commun 44:205-210.
49. Matsuo H, Baba Y, Nair RMG, Arimura A, Schally AV (1971) Structure of the porcine LH- and FSH-releasing hormone. I. The proposed amino acid sequence. Biochem Biophys Res Commun 43:1334-1339.
50. Okon E, Koch Y (1976) Localisation of gonadotropin-releasing and thyrotropin-releasing hormones in human brain by radioimmunoassay. Nature 263:345-347.
51. Tiscornia G, Singer O, Verma IM (2006) Production and purification of lentiviral vectors. Nat Protoc 1:241-245.
52. Chen A, et al. (2006) Urocortin 2-deficient mice exhibit gender-specific alterations in circadian hypothalamus-pituitary-adrenal axis and depressive-like behavior. J Neurosci 26:5500-5510.
53. Neufeld-Cohen A, et al. (2009) Urocortin-1 and -2 double-deficient mice show robust anxiolytic phenotype and modified serotonergic activity in anxiety circuits. Mol Psychiatry, 10.1038/mp.2009.115.